Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy

Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97(3):212-8. PMID: 29393194.

Abstrak        

Latar belakang: studi fase III mendemonstrasikan bahwa terapi eradikasi Helicobacter pylori menggunakan vonoprazan memiliki tingkat eradikasi yang lebih tinggi daripada lansoprazole. Akan tetapi, belum ada studi yang mengevaluasi efektivitas vonoprazan pada sampel berskala besar. Studi ini menginvestigasi tingkat eradikasi dan keamanan terapi vonoprazan dibandingkan dengan uji acak terkontrol yang menggunakan proton pump inhibitors (PPIs) generasi kedua.